Back to Journals » OncoTargets and Therapy » Volume 9

Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example

Authors Gerratana L, De Maglio G, De Pellegrin A, Follador A, Rihawi K, Pizzolitto S, Puglisi F, Fasola G

Received 21 January 2016

Accepted for publication 9 April 2016

Published 30 August 2016 Volume 2016:9 Pages 5399—5404

DOI https://doi.org/10.2147/OTT.S104748

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Triparna Sen

Peer reviewer comments 2

Editor who approved publication: Dr William Cho


Lorenzo Gerratana,1,2 Giovanna De Maglio,3 Alessandro De Pellegrin,3 Alessandro Follador,1 Karim Rihawi,1,2 Stefano Pizzolitto,3 Fabio Puglisi,1,2 Gianpiero Fasola1

1Department of Oncology, University Hospital of Udine, 2Department of Medical and Biological Sciences, University of Udine, 3Department of Pathology, University Hospital of Udine, Udine, Italy

Abstract: Molecular characterization is increasingly changing clinical practice, in both diagnosis and treatment. BRAF is a proto-oncogene that is mutated in ~2%–4% of lung cancers, but the incidence rises to 40%–45% among papillary thyroid cancers. Furthermore, BRAF is a promising target in lung cancer treatment. The present case study covers both the challenges of molecular differential diagnosis and the perspectives opened by targeted therapy by discussing the history of a 78-year-old female affected by a papillary histotype carcinoma with BRAF mutation associated with both thyroid and lung localizations. A differential diagnosis was possible as a consequence of a multidisciplinary approach including an in-depth molecular characterization. Based on this molecular feature, the patient was successfully treated with the BRAF inhibitor dabrafenib after the failure of treatment with standard regimen. To the best of our knowledge, this is the first published case of non-small-cell lung cancer with metastasis to thyroid and with BRAF V600E mutation.

Keywords: BRAF mutation, molecular diagnosis, target therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]